Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

haleon denmark aps - nicotinum resin-komplex - lyfjatyggigúmmí - 2 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

haleon denmark aps - nicotinum resin-komplex - lyfjatyggigúmmí - 4 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

haleon denmark aps - nicotinum polacrillin - lyfjatyggigúmmí - 2 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf. - pemetrexedum inn - innrennslisþykkni, lausn - 25 mg/ml

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

medical developments ned b.v. - methoxyflurane - innöndunargufa, gegndreyptur stabbi - 3 ml

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

merck sharp & dohme b.v. - pneumococcal polysaccharide danish types 1,2,3,4,5,6b,7f,8,9n,9v,10a,11a,12f,14,15b,17f,18,c,19a, 19f,20,22f,23f,33f - stungulyf, lausn í áfylltri sprautu - 25 míkróg

Den Europæiske Union - islandsk - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - aðrar húðsjúkdómar - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

sanofi pasteur* - salmonella typhi vi antigen - stungulyf, lausn - 25 míkróg/0,5 ml

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

sanofi pasteur* - filamentous haemagglutinin; poliovirus inactivated type 2; poliovirus inactivated type 3; diphtheria toxoid; tetanus toxoid; poliovirus inactivated type 1; pertussis toxoid; haemophilus influenzae type b - stungulyfsstofn og dreifa, dreifa

Den Europæiske Union - islandsk - EMA (European Medicines Agency)

tetris pharma b.v - glúkagon - sykursýki - brisi hormón, glycogenolytic hormón - ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.